{"entity":{"id":"nct04296175","kind":"trial","name":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","aka":["CITRINE"],"tldr":"A phase 3 trial of epirubicin, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Fudan University, active but no longer recruiting.","summary":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) is a phase 3, randomised interventional study registered as NCT04296175 by Fudan University, with a registry enrolment figure of 808 participants, started 2020-03-05 and due to reach its primary completion in 2025-03-10. Interventions recorded: Epirubicin; CTX; Paclitaxel; ddEpirubicin; ddCTX; Paclitaxel(with carbo); Carboplatin. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER, and PR expression)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04296175","url":"https://clinicaltrials.gov/study/NCT04296175"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["epirubicin","paclitaxel","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04296175","phase":"3","setting":"A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficacy and Safety of Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Combined With Carboplatin for High-risk, Triple-negative Early Breast Cancer","sponsor":"Fudan University","enrolled":808,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04296175/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}